Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WHP Omega 3 is a nutraceutical dietary supplement developed by Homeosyn Italia, formulated as oral softgels (perles). It contains a 72.4% concentration of fish oil, providing a 50% concentration of the omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The product is indicated for the management of dyslipidemia and lipid metabolism disorders due to its ability to lower cholesterol and normalize triglyceride levels. Its mechanism involves the activation of prostaglandins and acting as a natural antioxidant. It is also utilized as an adjuvant in antihypertensive therapy and is marketed through pharmacies in Italy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WHP Omega 3.